Often times, the reason cancer arises is due to a genetic change to genes. Genes are portions of DNA that control how cells function. These genetic changes can be passed down from parents, or can be due to some internal or external environmental factor, such as tobacco smoke. Mutations are a common genetic change that may occur. Similar cancers in different people as well as different cancers in similar people may all have diverse combinations of genetic changes that cause the cancer to arise.
Based on existing research, Epigenetic Data Sciences (EDS) has been able to identify the genes we believe show abnormal gene expression in breast cancer cells. Our research is based on the collected and analyzed data produced in laboratories and universities around the globe.
EDS’ approach is to fight cancer along all of it’s critical pathways that are drivers of cancer formation and progression. In contrast, one of the newest drugs for breast cancer, Ibrance, targets just two genes (CDK4 and CDK6)1.
At EDS, we have set our sights on well over a hundred-eighty genes that are either under or over-expressed in cancer cells. Our research aims to provide actionable information that not only targets the bad genes (oncogenes) that are over produced, but good (tumor – suppressors) that are under produced. We believe that this leads to a more comprehensive strategy to attack a disease that has defied a cure for centuries despite modern medicine’s best efforts.
The researchers on our EDS team are committed to delivering sustainable, non-toxic self-care options for people who are fighting cancer. We re excited about the launch of our first product for our Cancer Division — OncoSC Breast Support.
In addition to breast cancer, our team is working hard to develop new, science-based protocols that attack cancer cells for various types of cancer. A supplement protocol for lung cancer is the next product that we expect to launch within a year.